Standard BioTools Files 8-K for Financials and Exhibits
Ticker: LAB · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1162194
| Field | Detail |
|---|---|
| Company | Standard Biotools Inc. (LAB) |
| Form Type | 8-K |
| Filed Date | Dec 20, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $890,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, financials, exhibits
TL;DR
Standard BioTools filed an 8-K for financial statements and exhibits as of 12/19/24.
AI Summary
Standard BioTools Inc. filed an 8-K on December 20, 2024, reporting events as of December 19, 2024. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided excerpt. The company, formerly Fluidigm Corp, is incorporated in Delaware and headquartered in South San Francisco, California.
Why It Matters
This filing indicates Standard BioTools is providing updated financial statements and exhibits to the SEC, which is standard procedure for public companies and may contain important operational or financial details.
Risk Assessment
Risk Level: low — This filing appears to be routine and does not disclose any immediate significant risks or material changes.
Key Numbers
- 001-34180 — SEC File Number (Identifies the company's filing history with the SEC.)
- 77-0513190 — I.R.S. Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- Standard BioTools Inc. (company) — Registrant
- Fluidigm Corp (company) — Former Company Name
- December 19, 2024 (date) — Date of earliest event reported
- December 20, 2024 (date) — Filing Date
- South San Francisco, California (location) — Principal Executive Offices
FAQ
What specific financial statements or exhibits are being filed?
The filing indicates 'Financial Statements and Exhibits' are being reported, but the specific details of these documents are not provided in the excerpt.
Has Standard BioTools Inc. undergone any recent name changes?
Yes, the company was formerly known as Fluidigm Corp, with a date of name change noted as November 13, 2001.
What is the primary business address of Standard BioTools Inc.?
The principal executive offices are located at 2 Tower Place, Suite 2000, South San Francisco, California 94080.
What is the fiscal year end for Standard BioTools Inc.?
The fiscal year end for Standard BioTools Inc. is December 31.
What is the SIC code for Standard BioTools Inc.?
The Standard Industrial Classification (SIC) code for Standard BioTools Inc. is 3826, which corresponds to Laboratory Analytical Instruments.
Filing Stats: 781 words · 3 min read · ~3 pages · Grade level 11.2 · Accepted 2024-12-20 16:14:50
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share LAB Nasdaq Glob
- $890,000 — the Fee Application and agreeing to pay $890,000 in attorneys' fees and expenses in full
Filing Documents
- lab-20241219.htm (8-K) — 48KB
- lab-ex99_1.htm (EX-99.1) — 6KB
- lab-ex99_1s1.jpg (GRAPHIC) — 599KB
- lab-ex99_1s2.jpg (GRAPHIC) — 710KB
- lab-ex99_1s3.jpg (GRAPHIC) — 464KB
- lab-ex99_1s4.jpg (GRAPHIC) — 603KB
- lab-ex99_1s5.jpg (GRAPHIC) — 325KB
- lab-ex99_1s6.jpg (GRAPHIC) — 257KB
- 0000950170-24-139051.txt ( ) — 4272KB
- lab-20241219.xsd (EX-101.SCH) — 51KB
- lab-20241219_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On December 13, 2023, Plaintiffs Dr. Larry Gold and Dr. Jason Cleveland (together, the "Plaintiffs"), on behalf of a putative class of former stockholders of Nominal Defendant SomaLogic, Inc. ("SomaLogic"), a wholly owned subsidiary of Standard BioTools Inc. (the "Company"), filed a Verified Class Action Complaint (the "Action") in the Court of Chancery of the State of Delaware (the "Delaware Court"), alleging that the defendants breached their duty of disclosure by issuing an allegedly materially false and misleading proxy statement (the "Proxy"). On December 21, 2023, SomaLogic filed corrective and supplemental merger disclosures to the Proxy (the "Mooting Disclosures"). On September 3, 2024, the Plaintiffs filed a Motion for an Interim Award of Attorneys' Fees and Expenses seeking an award of attorneys' fees and expenses incurred by the Plaintiffs in securing the Mooting Disclosures (the "Fee Application"). SomaLogic denies and continues to deny all allegations of wrongdoing in the Action. Plaintiffs and SomaLogic agreed that the Mooting Disclosures rendered moot certain of Plaintiffs' claims. Following negotiations, the Company subsequently decided to avoid further litigation of the issue by resolving the Fee Application and agreeing to pay $890,000 in attorneys' fees and expenses in full satisfaction of any and all claims by Plaintiffs and their counsel for fees and expenses in the Action relating to the Mooting Disclosures. In making this decision, SomaLogic and the Company considered various factors, including the cost and time associated with litigation. On December 19, 2024, the Delaware Court entered an order, pursuant to a stipulation, providing that notice of these payments be given through the filing of this Current Report on Form 8-K. A copy of the Stipulation and [Proposed] Order Governing Plaintiffs' Motion for An Interim Award of Attorneys' Fees and Expenses is attached hereto as Exhibit 99.1 and is incorporated herein
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Stipulation and [Proposed] Order Governing Plaintiffs' Motion for An Interim Award of Attorneys' Fees and Expenses dated December 19, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 20, 2024 STANDARD BIOTOOLS INC. By: /s/ Alex Kim Name: Alex Kim Title: Chief Financial Officer